8,618 GPs for MedifyRemote(TM)

Stafford, England (ots/PRNewswire) - A group of 8,618 GPs have
today requested MedifyRemote(TM). The GPs interest in
MedifyRemote(TM) comes as a direct result of the company's first
marketing initiative.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070122/TO462LOGO )

Delivery and fulfilment of this groups requirements will now
commence giving strong penetration of MedifyRemote(TM) into the
US$1.2B NHS mobile data communications market.

Today's result marks the start of an aggressive sales and
marketing campaign launched by Medify Solutions Limited. Next step
activity includes a direct email marketing campaign to UK primary
caregivers, joint marketing activity with partners EMIS, further
partnership activity with Vodafone UK.

Nik Ellwood, Head of Sales and Marketing for Medify Solutions
Limited, comments, "This news is a significant milestone in
delivering true commercial value from the potential offered by
MedifyRemote(TM). We have been confident throughout in the impact our
application will have on healthcare in the NHS and are now, in the
very early stages of offering the product to the market, reaping the
rewards of all our hard work."

Notes for interested parties:

- MedifyRemote(TM) is a subscription based application available
at a cost of US$50 per month.

- MedifyRemote(TM) is the first secure mobile patient note access
application to enter field use throughout the NHS.

- MedifyRemote(TM) allows the healthcare professional to access,
review and update the patients' complete medical history in a single,
secure session via a Microsoft Windows enabled PDA device.

- MedifyRemote is a Vodafone Certified Application

This news release contains forward-looking statements that are
subject to certain risks and uncertainties that may cause actual
results to differ materially from those projected on the basis of
such forward-looking statements. The words "estimate," "project,"
"intends," "expects," "believes," and similar expressions are
intended to identify forward-looking statements. Such
forward-looking statements are made based on management's beliefs,
as well as assumptions made by, and information currently available
to, management pursuant to the "safe-harbour" provisions of the
Private Securities Litigation Reform Act of 1995. For a more
complete description of these and other risk factors that may affect
the future performance of Medify Solutions Limited, see "Risk
Factors" in the Company's Annual Report on Form 10-KSB and its other
filings with the Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date made and the Company
undertakes no obligation to disclose any revision to these
forward-looking statements to reflect events or circumstances after
the date made or to reflect the occurrence of unanticipated events.

ots Originaltext: Medify Solutions Ltd.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Nik Ellwood, +44-(0)845-0344090,
enquiries@medifysolutions.com or visit www.medifysolutions.com